Ocuphire Pharma, Inc. (OCUP)
| Market Cap | 76.78M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -22.37M |
| Shares Out | 20.81M |
| EPS (ttm) | -1.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 55,101 |
| Open | 3.69 |
| Previous Close | 3.60 |
| Day's Range | 3.53 - 3.69 |
| 52-Week Range | 1.78 - 4.43 |
| Beta | -0.07 |
| Analysts | Buy |
| Price Target | 21.62 (+485.91%) |
| Earnings Date | May 11, 2023 |
About OCUP
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also de... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for OCUP stock is "Buy." The 12-month stock price forecast is $21.62, which is an increase of 485.91% from the latest price.
News
Ocuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual Meeting
Oral Presentation to Feature Results from ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy Patients
Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings
Topline Data from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy Presented on February 11 th at 20 th Angiogenesis, Exudation, and Degeneration 2023 Meeting
Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of Mydriasis
If Approved Later This Year, Nyxol Could be the Only Commercially Available Eye Drop for Reversal of Dilation If Approved Later This Year, Nyxol Could be the Only Commercially Available Eye Drop for R...
What Makes Ocuphire Pharma, Inc. (OCUP) a Strong Momentum Stock: Buy Now?
Does Ocuphire Pharma, Inc. (OCUP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why Is Ocuphire Pharma (OCUP) Stock Down 20% Today?
Ocuphire Pharma (NASDAQ: OCUP) stock is falling on Thursday after the company posted results from a Phase 2 clinical trial. The clinical trial evaluated the use of APX3330 as a treatment for diabetic...
Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA
Oral APX3330 Achieved Statistical Significance on a Key Pre-specified Secondary Endpoint of Preventing Clinically Meaningful Progression of Diabetic Retinopathy (DR) after 24 Weeks of Treatment
Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia
Nyxol ® Eye Drops Potentially Offer Differentiated Mechanism of Action to Treat Age-Related Blurry Near Vision
Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis
NDA Supported by Positive Phase 3 Data Demonstrating Rapid Reversal of Dilated Eyes and Favorable Safety Profile in Pediatric and Adult Subjects NDA Supported by Positive Phase 3 Data Demonstrating Ra...
Ocuphire Pharma, Inc. (OCUP) Just Flashed Golden Cross Signal: Do You Buy?
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Ocuphire to Present at Five Upcoming Investor/Industry Conferences
FARMINGTON HILLS, Mich., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapi...
Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances
Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties
Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update
NDA Submission for Nyxol for RM and Initiation of VEGA-2 on Track for Q4 2022
Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA)
FARMINGTON HILLS, Mich., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapi...
All You Need to Know About Ocuphire Pharma, Inc. (OCUP) Rating Upgrade to Buy
Ocuphire Pharma, Inc. (OCUP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting
FARMINGTON HILLS, Mich., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapi...
Ocuphire Pharma to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference
Ocuphire to Present on Wednesday, October 12th @ 2:30 PM CT Ocuphire to Present on Wednesday, October 12th @ 2:30 PM CT
Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Disease
Virtual Webinar to Take Place Friday, October 14 th @ 11 AM ET
Ocuphire Expands Medical Advisory Board with Seven New KOLs and Strengthens Leadership Team
FARMINGTON HILLS, Mich., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therap...
Ocuphire Announces Upcoming Presentations at European Forum 2022, Eyecelerator@AAO 2022 and the American Academy of Ophthalmology 2022 Annual Meeting
FARMINGTON HILLS, Mich., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therap...
Ocuphire Pharma Receives PDFUA Fee Waiver for Nyxol New Drug Application from FDA
NDA Submission for Nyxol Eye Drops in First Indication on Track for Late 2022 NDA Submission for Nyxol Eye Drops in First Indication on Track for Late 2022
Ocuphire Pharma Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy
Top-line Results are Expected in 4Q 2022
Ocuphire Pharma to Present at The H.C. Wainwright 24th Annual Global Investment Conference
FARMINGTON HILLS, Mich., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therap...
Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update
Completed Final Clinical Trials and Pre-NDA FDA Meeting to Support Registration of Nyxol in Reversal of Mydriasis (RM), On Track for Late 2022 NDA Submission and Potential 2023 Approval
Ocuphire Pharma Announces Upcoming Presentations at Two Conferences in August
Canaccord Genuity 42 nd Annual Growth Conference on August 10, 2022
Ocuphire Extends U.S. Patent Protection for Late-Stage Drug Candidate Nyxol® for Reversal of Mydriasis by Five More Years into 2039 with New Patent Issuance
Issuance Extends Nyxol's U.S. Patent Protection from 2034 into 2039 for RM Indication